Envista (NYSE:NVST) PT Lowered to $17.00 at Robert W. Baird

Envista (NYSE:NVST) had its price target decreased by Robert W. Baird from $19.00 to $17.00 in a report released on Monday morning, Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

A number of other analysts have also weighed in on the stock. Needham & Company LLC reissued a hold rating on shares of Envista in a report on Tuesday, July 16th. The Goldman Sachs Group reduced their price objective on shares of Envista from $20.00 to $17.50 and set a sell rating on the stock in a research note on Friday, May 3rd. Morgan Stanley cut shares of Envista from an overweight rating to an equal weight rating and reduced their price objective for the company from $33.00 to $21.00 in a research note on Friday, April 26th. Evercore ISI reduced their price objective on shares of Envista from $24.00 to $19.00 and set an outperform rating on the stock in a research note on Tuesday, June 25th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Envista from $29.00 to $23.00 and set an overweight rating on the stock in a research note on Thursday, May 2nd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Envista currently has an average rating of Hold and a consensus target price of $22.65.

Envista Stock Performance

NYSE NVST opened at $16.29 on Monday. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -22.63, a PEG ratio of 13.66 and a beta of 1.31. The company has a 50 day moving average of $17.34 and a 200-day moving average of $20.12. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.34. Envista has a 1-year low of $15.69 and a 1-year high of $36.14.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). The company had revenue of $623.60 million during the quarter, compared to analyst estimates of $634.85 million. Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The business’s revenue for the quarter was down .6% on a year-over-year basis. During the same period in the prior year, the business earned $0.38 EPS. On average, equities analysts forecast that Envista will post 1.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

A number of hedge funds and other institutional investors have recently made changes to their positions in NVST. Van Lanschot Kempen Investment Management N.V. raised its holdings in shares of Envista by 32.9% during the second quarter. Van Lanschot Kempen Investment Management N.V. now owns 2,936,916 shares of the company’s stock worth $48,841,000 after acquiring an additional 727,406 shares during the period. Hedges Asset Management LLC acquired a new stake in shares of Envista during the second quarter worth $532,000. Shayne & Jacobs LLC raised its holdings in shares of Envista by 12.0% during the second quarter. Shayne & Jacobs LLC now owns 62,600 shares of the company’s stock worth $1,041,000 after acquiring an additional 6,700 shares during the period. Leeward Investments LLC MA raised its holdings in shares of Envista by 1.1% during the second quarter. Leeward Investments LLC MA now owns 640,589 shares of the company’s stock worth $10,653,000 after acquiring an additional 6,982 shares during the period. Finally, Raymond James & Associates raised its holdings in shares of Envista by 22.6% during the second quarter. Raymond James & Associates now owns 1,032,350 shares of the company’s stock worth $17,168,000 after acquiring an additional 190,240 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.